We are thrilled to share our insights from the ETERNAL 43M General Assembly held at the Universität des Saarlandes in Saarbrücken last week. Our experts Diego Hernández and Mario López engaged with the partners of the ETERNAL consortium to advance sustainable practices in pharmaceutical development.
The ETERNAL project is at the forefront of transforming pharmaceutical processes to reduce environmental impacts throughout their entire life cycle. This collaborative effort brings together experts from academia and industry to tackle critical challenges in pharmaceutical manufacturing, ensuring safe and effective medicines for all while protecting our planet.
During the assembly, several enlightening case studies highlighting innovative approaches to sustainability were explored:
- Sustainable Bio-manufacturing: Advancements in strain engineering are leading to greener production methods that minimize toxic by-products, making pharmaceutical manufacturing safer and more efficient.
- Continuous Manufacturing: Innovations such as Twin Screw Granulation and continuous microfluidic processes enhance efficiency and reduce energy consumption, paving the way for eco-friendly drug production.
- Green Chemistry Applications: The integration of organic solvent nanofiltration technology is revolutionizing solvent exchange, reducing energy demands and minimizing waste in drug synthesis.
- Ecotoxicity Research: Continued efforts in ecotoxicological studies are essential in assessing the environmental impact of pharmaceuticals, guiding future innovations toward safer solutions.
Together, we are committed to fostering the sustainable development of pharmaceuticals, ensuring that both human health and environmental integrity are prioritized.
Let’s work hand-in-hand towards a greener future!
For more information about the ETERNAL project, visit www.eternalproject.eu
Need help in your Regulatory projects? Contact us! [email protected]
